Pasithea Therapeutics Quick Ratio (KTTA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pasithea Therapeutics Corp   (NASDAQ: KTTA)

Pasithea Therapeutics 's Quick Ratio

KTTA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Pasithea Therapeutics 's Cash & cash equivalent grew by 81.47 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Pasithea Therapeutics 's Quick Ratio to 49.76, above Pasithea Therapeutics Corp average Quick Ratio.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Quick Ratio than Pasithea Therapeutics in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 62.

Explain Quick Ratio?
How much Cash & cash equivalents KTTA´s has?
What are KTTA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KTTA Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
2025		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 16.21 % 12.34 % 1 % 102.57 % 139.48 %
Y / Y Cash & cash equivalent Change 1167.33 % 843.6 % 1495.02 % -55.96 % -22.9 %
Quick Ratio MRQ 49.76 33.84 97.62 3.08 4.56
KTTA's Total Ranking # 62 # 0 # 623 # 512 #
Seq. Current Liabilities Change 23.39 % 31.69 % -15.45 % -15.41 % 19.28 %
Seq. Cash & cash equivalent Change 81.47 % -54.36 % 2578.15 % -42.87 % 35.12 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 10
Overall Market # 62


Quick Ratio Statistics
High Average Low
97.62 22.86 3.08
(Dec 31 2025)   (Sep 30 2025)




Financial Statements
Pasithea Therapeutics 's Current Liabilities $ 2 Millions Visit KTTA's Balance sheet
Pasithea Therapeutics 's Cash & cash equivalent $ 91 Millions Visit KTTA's Balance sheet
Source of KTTA's Sales Visit KTTA's Sales by Geography


Cumulative Pasithea Therapeutics 's Quick Ratio

KTTA's Quick Ratio for the trailling 12 Months

KTTA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 23.65 % 47.08 % 10.29 % -14.94 % -37.63 %
Y / Y Cash & cash equivalent TTM Growth 788.99 % 455.6 % 237.54 % -49.85 % -49.74 %
Quick Ratio TTM 44.24 31.08 23.64 4.4 6.15
Total Ranking TTM # 2666 # 0 # 2879 # 2789 #
Seq. Current Liabilities TTM Growth 4.63 % 3.04 % 0.21 % 14.45 % 24.46 %
Seq. Cash & cash equivalent TTM Growth 48.94 % 35.45 % 438.47 % -18.16 % -6.92 %

Quick ratio ranking by company, industry and sector >> Back to KTTA Financial Strength Comparisons >> Go to Compare KTTA Quick Ratio to its Competitors

On the trailing twelve months basis KTTA Cash & cash equivalent more than doubled by 1167.33 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Pasithea Therapeutics 's Quick Ratio to 44.24, above KTTA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 397 other companies have achieved higher Quick Ratio than Pasithea Therapeutics . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 0 to 2666.

Explain Quick Ratio?
How much Cash & cash equivalents KTTA´s has?
What are KTTA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 398
Healthcare Sector # 775
Within the Market # 2666


trailing twelve months Quick Ratio Statistics
High Average Low
43.22 16.18 5.64
(Sep 30 2022)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Enliven Therapeutics Inc   116.86 $ 1,654.850  Millions$ 14.161  Millions
Acrivon Therapeutics Inc   104.48 $ 89.959  Millions$ 0.861  Millions
Arca Biopharma Inc  87.05 $ 2,225.581  Millions$ 25.566  Millions
Tango Therapeutics Inc   82.19 $ 1,668.432  Millions$ 20.299  Millions
Contineum Therapeutics Inc   70.25 $ 458.440  Millions$ 6.526  Millions
Sagimet Biosciences inc   61.23 $ 331.832  Millions$ 5.419  Millions
Avalyn Pharma Inc   49.93 $ 539.733  Millions$ 10.809  Millions
Pasithea Therapeutics Corp   49.76 $ 91.464  Millions$ 1.838  Millions
Disc Medicine Inc   44.03 $ 1,336.770  Millions$ 30.360  Millions
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions

Date modified: 2026-08-17T07:26:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.